Swiss imaging software developer Medimaps Group plans to merge with Danish firm Radiobotics, combining both AI-driven musculoskeletal imaging software companies into a single global provider.
The new company will offer AI-enabled imaging software for x-ray and dual energy x-ray absorptiometry (DEXA) indications, such as automated fracture detection, opportunistic bone fragility assessment, and fracture risk prediction. Medimaps Group's bone microarchitecture offerings -- TBS Osteo and TBS Reveal -- will be integrated into Radiobotics' RBfracture, that firm's main software for detecting trauma-related findings such as fractures, dislocations, and effusions, the two companies said.
The merged organization will serve hospitals, clinics, and imaging centers across 90 countries. Both firms will maintain their existing brands. The deal is pending Danish foreign direct investment approval and other closing conditions, and financial terms were not disclosed.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
